Revance Therapeutics Investor Presentation — September 2020

Document content

COMPANY PRESENTATION

September 2020FORWARD -LOOKING STATEMENTS / SAFE HARBOR / MARKET DATA

This presentation contains forward -looking statements, including forward -statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements

relate to: financial metrics and outlook; the growth of markets for global neuromodulators, dermal fillers and aesthetics fintec h platforms; the process and timing of, and ability to

complete, current and anticipated future clinical development of our investigational product candidates, including anticipate d near-term milestones; development of a biosimilar to

BOTOX®; timing and outcome of regulatory determinations regarding potential approval of DaxibotulinumtoxinA for Injection and expected PDUFA date and commercial potential of

our drug candidates; anticipated strategic and financial benefits of our distribution agreement with Teoxane; the expected benef its of the acquisition of the HintMD platform and

related technologies to Revance and the combined business; commercial acceptance and potential of our drug product candidates an d our technologies, including with respect to the

RHA line of dermal fillers; status of commercial collaborations, including collaboration agreement with Mylan, demand for our product candidates and drivers of demand; market size,

adoption rate and potential revenue; growth opportunities and product pipeline; our business strategy, timeline and other goa ls and market for our anticipated products, plans and

prospects, including our pre -commercialization plans; our ability to leverage our investment in our development and manufacturin g platform; and our commercial and intellectual

These forward -looking statements are subject to the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Revance’s expectations and beliefs regarding

these matters may not materialize. Actual outcomes and results may differ materially from those contemplated by these forward -looking statements as a result of uncertainties, risks

and changes in circumstances, including but not limited to risks and uncertainties included under the caption “Risk Factors” an d elsewhere in Revance’s most recent filings with the

SEC, including Revance’s Quarterly Report on Form 10 -Q for the quarter ended June 30, 2020 and any subsequent reports filed wit h the SEC from time to time and available

atwww.sec.gov . These documents can be accessed on the Revance Investor Relations page at https://investors.revance.com/ by clicking on the link titled “Financials and

Filings.” The risks and uncertainties may be amplified by the COVID -19pandemic, which has caused significant economic uncertai nty. The extent to which the COVID -19pandemic